

Enabling Next-Gen Cell Therapy

Our leadership team has a combined two decades of experience in medtech and biotech



Nikhil Joshi Co-founder, CEO













Marcus Foley Co-founder, CTO












Cell Therapy (CT) as a treatment option has been a game-changer in blood-based diseases



The CT industry is moving into solid tissue diseases, which require *localized cell delivery*



The delivery tools available today for administration


of cells are inadequate


Hospital-side prep lacks control and standardization¹

Current devices don't get cells to target tissue²

Infusion process kills or damages cells²

Low cell product yield¹
Poor cell engraftment¹
Inflammatory response¹
Need for higher/multiple doses²









Researchers have described these problems across

multiple contexts





SCIENCE TRANSLATIONAL MEDICINE | REVIEW

STEM CELLS

Locoregional delivery of stem cell-based therapies



predisposition




We are building a modular system specifically designed to deliver cells

Our system:

- Standardizes the tx administration process
- Allows clinicians to deliver cells locally
- Reduces damaging factors during infusion
- Enables intelligent delivery of cells

Odyssey Robotic Infusion System*

Serene Infusion Kits*




*Patents and Trademark Pending




Our first product is a manual infusion kit for local cell therapy administration

Serene Infusion Kit*

- Improve yield of final step of cell therapy delivery
- Improve functionality of cells post-infusion
- Reduce variability of tx administration between providers






^{**}Patents and Trademark Pending




Preclinical research of the Serene system shows improvement in CT Yield

CV In-vitro Results: Infusions through Serene improve MSC viability and functionality compared to off-the-shelf devices



Therapeutic Impact: Viability differences of just 14% have significant effects on MSC therapeutic efficacy (University of Wisconsin)



Cell Therapy Journey

Cell Harvesting

Cell Therapy Design and Manufacture

Transportation/ Logistics

AmerisourceBergen

cytiva

Vineti

World Courier

Cell Therapy Treatment Delivery

Post-delivery Cell Viability/Efficacy







culture [RESILIENCE







"Last Mile" patient-side delivery

Combo drug/delivery plays



Cellular Vehicles Offering

We are partnering with biotechs developing solid tissue CTs

Structure

 Co-development deal with biotechs developing solid-tissue cell therapies

∘CV Offering:

- Infusion kit tailored to CT indication (infusion device + custom access catheter)
- Data package to be plugged into CT IND applications
- CV to pursue 510(k) clearance (in time for CT commercialization)

Mutual Value of Partnership:

- For biotechs: outsourced development and regulatory approval of delivery device, improved CT viability and functionality vs. status quo/competition, lower dose/doses, improved last-step yield, lower cost of CT manufacture.
- For CV: translation of innovation to patient benefit, alternative source of funding, hardware platform validation.





What we need from you: Letter of Intent towards Exploratory Study

- Establish interest in an exploratory pilot study and future co-development deal
- Non-binding

Thursday, May 26, 2022

Pilot Study – Cell Therapy Performance Lab
Cellular Vehicles has built an in vitro "Cell
Therapy Performance Lab" - a research
model that measures performance of cell
therapies across variables like localization,
viability, functionality, engraftment, and
persistence. We're offering early partners the
chance to conduct pre-IND studies in this
model at cost. Contact us to learn more.



Nikhil Joshi Cellular Vehicles Inc. 55 E 3rd Avenue San Mateo, CA 94401

Dear Mr. Joshi

We are writing this letter to express our interest in collaborating with Cellular Vehicles ("CV") on the development of Cell Therapy ("CT") Administration technologies, which would be used in conjunction with our cell therapy product(s). Based on our preliminary review of your progress and testing conducted to date, we're confident in the potential for a mutually beneficial partnership. A product or set of products centered around your expertise in designing tools that standardize the therapeutic administration process and increase cell product yield would be of interest to us for use with our cell therapy product(s). The terms of a collaboration (to be defined in a separate term sheet) could include the following:

- CV to offer an infusion kit product designed for our CT product, which minimally includes an infusion device and access catheter.
- CV to provide a data package for this product which meets the requirements set forth by the FDA for an IDE (investigational device exemption), which can be plugged into the IND application (to be completed by us).
- CV to independently push the aforementioned product through the FDA 510(k) application process, including but not limited to the following tasks:
 - a. conducting an FDA pre-sub meeting to agree upon predicate devices and claims
 - b. establishing a Quality Management System meeting FDA requirements
 - c. completing Design Verification & Validation Testing
 - d. submitting the 510(k) application
- e. receiving approval for the marketing and sale of the product
- 4. CV to achieve 510(k) clearance in time for CT drug approval.

This letter of intent represents a non-binding indication of interest, and a separate term sheet document would be executed should the two parties decide to enter into formal agreement. This letter is not intended, and sha not be deemed, to create any binding obligation or relationship between our company and Cellular Vehicles.

We are excited about the potential opportunity and hope that you are equally interested in proceeding in a constructive and timely manner. We look forward to working with you to complete this transaction.

Sincerely,

Cellular Vehicles, Inc. 55 E 3rd Ave San Mateo, CA 94401

Confidential 11

Thank you!

Contact us if you're interested: nikhil@cellularvehicles.com

